Najat Khan Sells 36,599 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Key Points

• Insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals at an average price of $5.52, totaling approximately $202,026, which decreased their ownership by 5.19%.
• Recursion Pharmaceuticals reported a loss of $0.41 EPS in its latest quarter, missing estimates, despite a revenue increase of 33.3% year-over-year, totaling $19.10 million.
• The company has a current market cap of $2.21 billion with a consensus rating of "Hold" from analysts and a target price of $7.00.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) insider Najat Khan sold 36,599 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the sale, the insider owned 668,197 shares of the company's stock, valued at $3,688,447.44. This trade represents a 5.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Recursion Pharmaceuticals Price Performance

RXRX stock traded up $0.16 on Friday, reaching $4.94. 19,864,289 shares of the company's stock were exchanged, compared to its average volume of 19,735,188. The stock has a fifty day moving average of $5.46 and a 200-day moving average of $5.74. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The firm has a market cap of $2.14 billion, a PE ratio of -2.78 and a beta of 0.93. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The firm had revenue of $19.10 million for the quarter, compared to analysts' expectations of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The firm's revenue for the quarter was up 33.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Liontrust Investment Partners LLP grew its position in shares of Recursion Pharmaceuticals by 18.0% in the second quarter. Liontrust Investment Partners LLP now owns 702,386 shares of the company's stock valued at $3,554,000 after purchasing an additional 107,331 shares during the period. Hudson Bay Capital Management LP boosted its holdings in Recursion Pharmaceuticals by 18.0% in the second quarter. Hudson Bay Capital Management LP now owns 150,000 shares of the company's stock valued at $759,000 after acquiring an additional 22,930 shares during the last quarter. Headlands Technologies LLC boosted its holdings in Recursion Pharmaceuticals by 20.2% in the second quarter. Headlands Technologies LLC now owns 199,415 shares of the company's stock valued at $1,009,000 after acquiring an additional 33,565 shares during the last quarter. Sender Co & Partners Inc. acquired a new position in Recursion Pharmaceuticals in the second quarter valued at $121,000. Finally, HRT Financial LP acquired a new position in Recursion Pharmaceuticals in the second quarter valued at $2,753,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target for the company. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.